BR112016015399A2 - método, método de tratamento de um sujeito, método de melhorar a eficácia da terapia do câncer, método para tratamento do câncer, método de tratamento de um câncer e método de definição de uma assinatura de resposta para uma terapia de modulador do ponto de checagem imunológico - Google Patents

método, método de tratamento de um sujeito, método de melhorar a eficácia da terapia do câncer, método para tratamento do câncer, método de tratamento de um câncer e método de definição de uma assinatura de resposta para uma terapia de modulador do ponto de checagem imunológico

Info

Publication number
BR112016015399A2
BR112016015399A2 BR112016015399A BR112016015399A BR112016015399A2 BR 112016015399 A2 BR112016015399 A2 BR 112016015399A2 BR 112016015399 A BR112016015399 A BR 112016015399A BR 112016015399 A BR112016015399 A BR 112016015399A BR 112016015399 A2 BR112016015399 A2 BR 112016015399A2
Authority
BR
Brazil
Prior art keywords
treating
cancer
therapy
treating cancer
effectiveness
Prior art date
Application number
BR112016015399A
Other languages
English (en)
Portuguese (pt)
Inventor
Snyder Charen Alexandra
Wolchok Jedd
Chan Timothy
Makarov Vladimir
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of BR112016015399A2 publication Critical patent/BR112016015399A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BR112016015399A 2014-01-02 2014-12-23 método, método de tratamento de um sujeito, método de melhorar a eficácia da terapia do câncer, método para tratamento do câncer, método de tratamento de um câncer e método de definição de uma assinatura de resposta para uma terapia de modulador do ponto de checagem imunológico BR112016015399A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461923183P 2014-01-02 2014-01-02
US201462066034P 2014-10-20 2014-10-20
US201462072893P 2014-10-30 2014-10-30
PCT/US2014/072125 WO2015103037A2 (en) 2014-01-02 2014-12-23 Determinants of cancer response to immunotherapy

Publications (1)

Publication Number Publication Date
BR112016015399A2 true BR112016015399A2 (pt) 2017-10-24

Family

ID=53494217

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016015399A BR112016015399A2 (pt) 2014-01-02 2014-12-23 método, método de tratamento de um sujeito, método de melhorar a eficácia da terapia do câncer, método para tratamento do câncer, método de tratamento de um câncer e método de definição de uma assinatura de resposta para uma terapia de modulador do ponto de checagem imunológico

Country Status (15)

Country Link
US (1) US20160326597A1 (enExample)
EP (1) EP3090066A4 (enExample)
JP (1) JP2017504324A (enExample)
KR (1) KR20160102314A (enExample)
CN (1) CN106164289A (enExample)
AU (1) AU2014374020A1 (enExample)
BR (1) BR112016015399A2 (enExample)
CA (1) CA2935214A1 (enExample)
CL (1) CL2016001708A1 (enExample)
MX (1) MX2016008771A (enExample)
PE (1) PE20161344A1 (enExample)
PH (1) PH12016501329A1 (enExample)
RU (1) RU2707530C2 (enExample)
SG (2) SG10201805674YA (enExample)
WO (1) WO2015103037A2 (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
KR20170080697A (ko) 2014-11-13 2017-07-10 더 존스 홉킨스 유니버시티 관문 차단 및 미소부수체 불안정성
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
CA2987730C (en) 2015-04-08 2020-02-18 Nantomics, Llc Cancer neoepitopes
WO2016172722A1 (en) * 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
CN107847572A (zh) 2015-05-13 2018-03-27 艾吉纳斯公司 用于癌症治疗和预防的疫苗
GB201516047D0 (en) * 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
MX387275B (es) * 2015-10-12 2025-03-18 Nantomics Llc Neoepítopos virales y sus usos
CA3003251A1 (en) * 2015-10-12 2017-04-20 Nantomics, Llc Systems, compositions, and methods for discovery of msi and neoepitopes that predict sensitivity to checkpoint inhibitors
US11623001B2 (en) 2015-10-12 2023-04-11 Nantomics, Llc Compositions and methods for viral cancer neoepitopes
ES2961306T3 (es) 2015-10-23 2024-03-11 Novartis Ag Método para obtener un valor de porcentaje de positividad para un biomarcador para células seleccionadas presentes en un campo de visión
TWI733719B (zh) * 2015-12-07 2021-07-21 美商河谷控股Ｉｐ有限責任公司 改善的組合物及用於新表位之病毒遞送的方法及其應用
US20170199961A1 (en) 2015-12-16 2017-07-13 Gritstone Oncology, Inc. Neoantigen Identification, Manufacture, and Use
CN108472350A (zh) * 2016-01-08 2018-08-31 瓦西博迪公司 新表位rna癌症疫苗
WO2017143092A1 (en) 2016-02-19 2017-08-24 Nant Holdings Ip, Llc Methods of immunogenic modulation
KR102500659B1 (ko) 2016-02-29 2023-02-16 제넨테크, 인크. 암에 대한 치료 및 진단 방법
WO2017151517A1 (en) * 2016-02-29 2017-09-08 Foundation Medicine, Inc. Methods of treating cancer
US12065699B2 (en) 2016-03-15 2024-08-20 Repertoire Genesis Incorporation Monitoring and diagnosis for immunotherapy, and design for therapeutic agent
LT3429618T (lt) * 2016-03-16 2024-05-10 Amal Therapeutics Sa Imuninės sistemos patikros taško moduliatoriaus ir komplekso, apimančio į ląsteles prasiskverbiantį peptidą, krovinį ir tlr peptido agonistą, derinys, skirtas naudoti medicinoje
MX2018015352A (es) * 2016-06-10 2019-03-28 Io Therapeutics Inc Subtipos de receptores y compuestos retinoides y rexinoides de funcion selectiva combinados con moduladores inmunitarios para inmunoterapia contra el cancer.
WO2018005276A1 (en) * 2016-06-29 2018-01-04 The Johns Hopkins University Neoantigens as targets for immunotherapy
CN109963585B (zh) 2016-09-21 2024-10-15 阿尔勒治疗公司 包括细胞穿透肽、多表位和tlr肽激动剂的用于治疗癌症的融合物
EP3516081A4 (en) * 2016-09-23 2020-07-29 Memorial Sloan Kettering Cancer Center DETERMINANTS OF CANCER RESPONSE TO IMMUNOTHERAPY
MX2019003934A (es) * 2016-10-06 2019-07-10 Genentech Inc Métodos terapéuticos y de diagnóstico para el cáncer.
CN110214275B (zh) 2016-12-01 2022-12-06 南托米克斯有限责任公司 肿瘤抗原性加工和呈递
US11480572B2 (en) 2016-12-16 2022-10-25 Nantbio, Inc. Live cell imaging systems and methods to validate triggering of immune response
US20190369096A1 (en) * 2017-01-13 2019-12-05 Nantbio, Inc. Validation of neoepitope-based treatment
US12331359B2 (en) 2017-01-18 2025-06-17 Michael Laessig Neoantigens and uses thereof for treating cancer
WO2018146128A1 (en) * 2017-02-07 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy
EP3596231A1 (en) * 2017-03-17 2020-01-22 NantOmics, LLC LIQUID BIOPSY FOR cfRNA
SG10202110594UA (en) * 2017-03-31 2021-11-29 Bristol Myers Squibb Co Methods of treating tumor
EP3933408A1 (en) 2017-05-30 2022-01-05 Nant Holdings IP LLC Circulating tumor cell enrichment using neoepitopes
CN110996970A (zh) 2017-06-02 2020-04-10 亚利桑那州立大学董事会 创建个性化癌症疫苗的方法
US11984200B2 (en) * 2017-06-13 2024-05-14 Bostongene Corporation Systems and methods for generating, visualizing and classifying molecular functional profiles
GB201710815D0 (en) * 2017-07-05 2017-08-16 Francis Crick Inst Ltd Method
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
EP3684955A1 (en) 2017-09-20 2020-07-29 Regeneron Pharmaceuticals, Inc. Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden
AU2018338441B2 (en) * 2017-09-25 2025-08-14 Memorial Sloan Kettering Cancer Center Tumor mutational load and checkpoint immunotherapy
EP3688165A4 (en) 2017-09-25 2021-09-29 Nant Holdings IP, LLC VALIDATION OF THE PRESENTATION OF NEOEPITOPES
CN118888004A (zh) 2017-10-10 2024-11-01 磨石生物公司 使用热点进行的新抗原鉴别
EP3694884A1 (en) 2017-10-15 2020-08-19 Bristol-Myers Squibb Company Methods of treating tumor
JP7421474B2 (ja) 2017-11-03 2024-01-24 ガーダント ヘルス， インコーポレイテッド 腫瘍遺伝子変異量の正規化
EP3707272A4 (en) * 2017-11-09 2021-11-24 The Trustees of The University of Pennsylvania EXTRACELLULAR VESICULAR PROTEINS AND THEIR USE FOR CANCER DIAGNOSIS, PREDICTION OF RESPONSE TO THERAPY AND TREATMENT
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
US12367978B2 (en) 2017-12-01 2025-07-22 Illumina, Inc. Methods and systems for determining somatic mutation clonality
CN108009400B (zh) * 2018-01-11 2018-07-06 至本医疗科技（上海）有限公司 全基因组肿瘤突变负荷预测方法、设备以及存储介质
US11414698B2 (en) * 2018-03-22 2022-08-16 Chang Gung Medical Foundation Chang Gung Memorial Hospital At Chiayi Method of quantifying mutant allele burden of target gene
EP3784688A2 (en) 2018-04-26 2021-03-03 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
CN112752854B (zh) 2018-07-23 2025-03-18 夸登特健康公司 用于通过肿瘤分数和覆盖率调整肿瘤突变负荷的方法和系统
JP7539367B2 (ja) 2018-08-31 2024-08-23 ガーダント ヘルス， インコーポレイテッド 無細胞ｄｎａにおけるマイクロサテライト不安定性の検出
CN109371005B (zh) * 2018-11-12 2022-09-30 上海市东方医院（同济大学附属东方医院） 一种hla-0201限制性padi4表位多肽及其应用
EP3893932A4 (en) * 2018-12-12 2022-09-07 Medimmune, LLC BLOOD-BASED TUMORMUTATION LOAD AS A PREDICTOR OF OVERALL SURVIVAL IN NON-SMALL CELL LUNG CANCER
US20220081723A1 (en) * 2018-12-21 2022-03-17 Agency For Science, Technology And Research Method of predicting for benefit from immune checkpoint inhibition therapy
US12031181B2 (en) 2019-04-05 2024-07-09 Illumina, Inc. Quantitative score of HLA diversity
EP3977136A4 (en) * 2019-05-24 2023-05-10 Edifice Health, Inc. PRECISION DRUGS FOR CANCER IMMUNOTHERAPY
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
NL2024107B1 (en) * 2019-10-26 2021-07-19 Vitroscan B V Compositions for Patient Specific Immunotherapy
CN111088349B (zh) * 2020-02-14 2023-04-28 深圳市宝安区妇幼保健院 Kir3dl1基因分型引物组及其应用
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4000596A1 (en) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptide and compositions comprising tetrapeptides
EP4000595A1 (en) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptide and compositions comprising tetrapeptides
US20240192195A1 (en) * 2021-04-10 2024-06-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. A multiomic approach to modeling of gene regulatory networks in multiple myeloma
WO2023025404A1 (en) 2021-08-24 2023-03-02 BioNTech SE In vitro transcription technologies
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
WO2024216165A1 (en) 2023-04-12 2024-10-17 Icahn School Of Medicine At Mount Sinai Computational methods for selecting personalized neoantigen vaccines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826143D0 (en) * 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
US9222938B2 (en) * 2001-12-04 2015-12-29 Michael Tainsky Neoepitope detection of disease using protein arrays
WO2006050172A2 (en) * 2004-10-29 2006-05-11 University Of Southern California Combination cancer immunotherapy with co-stimulatory molecules
US20100099090A1 (en) * 2007-03-05 2010-04-22 Bristol-Mayers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
ES3038392T3 (en) * 2010-05-14 2025-10-13 Massachusetts Gen Hospital Neoantigen specific cytotoxic t cells for use in treating cancer
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
WO2012159643A1 (en) * 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer

Also Published As

Publication number Publication date
EP3090066A2 (en) 2016-11-09
RU2707530C2 (ru) 2019-11-27
RU2016131207A3 (enExample) 2018-06-22
RU2016131207A (ru) 2018-02-07
CL2016001708A1 (es) 2017-03-17
SG11201605432RA (en) 2016-07-28
MX2016008771A (es) 2016-12-20
PE20161344A1 (es) 2016-12-23
CN106164289A (zh) 2016-11-23
JP2017504324A (ja) 2017-02-09
WO2015103037A2 (en) 2015-07-09
PH12016501329A1 (en) 2016-10-03
KR20160102314A (ko) 2016-08-29
CA2935214A1 (en) 2015-07-09
EP3090066A4 (en) 2017-08-30
SG10201805674YA (en) 2018-08-30
US20160326597A1 (en) 2016-11-10
AU2014374020A1 (en) 2016-08-18
WO2015103037A3 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
BR112016015399A2 (pt) método, método de tratamento de um sujeito, método de melhorar a eficácia da terapia do câncer, método para tratamento do câncer, método de tratamento de um câncer e método de definição de uma assinatura de resposta para uma terapia de modulador do ponto de checagem imunológico
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
BR112017023821A2 (pt) moduladores de k-ras
IL270888A (en) Systems and methods for identifying cancer treatments from normalized biomarker scores
EP4393546A3 (en) Determinants of cancer response to immunotherapy by pd-1 blockade
MX379270B (es) Composiciones que comprenden cepas bacterianas.
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
CO2017004386A2 (es) Fluidos de estimulación de lgn de grado y
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
BR112019005305A2 (pt) compostos espirocíclicos
MX383484B (es) Método para tratar el cáncer.
BR112017012859A2 (pt) fosforamidatos para o tratamento do vírus da hepatite b
BR112016027222A2 (pt) anticorpos isolados, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de tratamento de um indivíduo com um câncer, de inibição da proliferação de uma célula, de detecção de gpc3 humano e de detecção de um câncer
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
EA201991818A1 (ru) Лечение рака
MX2020006297A (es) Variantes de cd19.
BR112018069303A2 (pt) método para tratamento de uma infecção
BR112018073238A2 (pt) vírus oncolíticos compreendendo esrage e métodos de tratamento de câncer
MX2017005888A (es) Dispositivos, sistemas y metodos para la deteccion de analitos.
BR112017005428A2 (pt) método para tratar uma formação subterrânea, sistema para realizar o método de tratamento de uma formação subterrânea, sistema, composição para o tratamento de uma formação subterrânea e método de preparar uma composição para o tratamento de uma formação subterrânea
MX382996B (es) Inhibidores de pcna
CY1123019T1 (el) Σπειροκυκλικες ενωσεις
BR112019001398A2 (pt) métodos para tratamento de câncer de próstata
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2610 DE 12-01-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.